Drugs / XJ103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06026748 | Sep 2023 → Dec 2024 | pneumococcal infection | Starmab biologics（Shanghai）Co,.ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XJ103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026748 ↗ |
| Modality | Monoclonal antibody | “XJ103 is a humanized monoclonal antibody.” NCT06026748 ↗ |
| Route | Intravenous | “Participants will receive a single dose of XJ103 intravenously.” NCT06026748 ↗ |